JP2004513626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513626A5 JP2004513626A5 JP2002526886A JP2002526886A JP2004513626A5 JP 2004513626 A5 JP2004513626 A5 JP 2004513626A5 JP 2002526886 A JP2002526886 A JP 2002526886A JP 2002526886 A JP2002526886 A JP 2002526886A JP 2004513626 A5 JP2004513626 A5 JP 2004513626A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- clusterin
- disease
- antisense oligonucleotide
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims 7
- 238000012230 antisense oligonucleotides Methods 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 102000003780 Clusterin Human genes 0.000 claims 6
- 108090000197 Clusterin Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 238000001246 colloidal dispersion Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/659,791 US6383808B1 (en) | 2000-09-11 | 2000-09-11 | Antisense inhibition of clusterin expression |
| PCT/US2001/028235 WO2002022635A1 (en) | 2000-09-11 | 2001-09-10 | Antisense modulation of clusterin expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009191924A Division JP2010043086A (ja) | 2000-09-11 | 2009-08-21 | クラスタリン発現のアンチセンスモジュレーション |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004513626A JP2004513626A (ja) | 2004-05-13 |
| JP2004513626A5 true JP2004513626A5 (enExample) | 2005-03-17 |
| JP4397585B2 JP4397585B2 (ja) | 2010-01-13 |
Family
ID=24646855
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002526886A Expired - Fee Related JP4397585B2 (ja) | 2000-09-11 | 2001-09-10 | クラスタリン発現のアンチセンスモジュレーション |
| JP2009191924A Pending JP2010043086A (ja) | 2000-09-11 | 2009-08-21 | クラスタリン発現のアンチセンスモジュレーション |
| JP2013156811A Pending JP2014027936A (ja) | 2000-09-11 | 2013-07-29 | クラスタリン発現のアンチセンスモジュレーション |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009191924A Pending JP2010043086A (ja) | 2000-09-11 | 2009-08-21 | クラスタリン発現のアンチセンスモジュレーション |
| JP2013156811A Pending JP2014027936A (ja) | 2000-09-11 | 2013-07-29 | クラスタリン発現のアンチセンスモジュレーション |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6383808B1 (enExample) |
| EP (1) | EP1325019B1 (enExample) |
| JP (3) | JP4397585B2 (enExample) |
| AT (1) | ATE496127T1 (enExample) |
| AU (1) | AU2001290706A1 (enExample) |
| DE (1) | DE60143901D1 (enExample) |
| WO (1) | WO2002022635A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040121973A1 (en) * | 2002-02-05 | 2004-06-24 | Monia Brett P | Antisense modulation of protein phosphatase 2 Catalytic subunit alpha expression |
| US6444650B1 (en) * | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| IL144975A0 (en) | 1999-02-26 | 2002-06-30 | Univ British Columbia | A composition containing an antisense oligonucleotide |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| KR101265180B1 (ko) * | 2002-01-17 | 2013-05-29 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물 |
| US20040102401A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of jagged 1 expression |
| JP2005532052A (ja) * | 2002-07-01 | 2005-10-27 | ファルマシア・コーポレーション | Ｌｒｈ１発現のアンチセンス調節 |
| KR101117673B1 (ko) * | 2002-08-21 | 2012-03-07 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| EP1530636B1 (en) * | 2002-08-21 | 2010-08-18 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
| WO2004092378A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| WO2004092379A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of angiogenic disorders |
| US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| EP1708730A2 (en) * | 2004-01-20 | 2006-10-11 | DeveloGen Aktiengesellschaft | Use of a dg147 protein product for preventing and treating metabolic disorders |
| JP2007520222A (ja) * | 2004-01-20 | 2007-07-26 | アイシス ファーマシューティカルズ インコーポレイテッド | グルココルチコイドレセプター発現の調節 |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| ITBZ20040048A1 (it) * | 2004-10-06 | 2005-01-06 | Genprofiler | Metodo per l'identificazione della trasformazione neoplastica, con particolare riferimento al cancro prostatico |
| DK1814595T3 (da) * | 2004-11-23 | 2014-03-31 | Univ British Columbia | Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne |
| RU2414236C2 (ru) | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| EA200900786A1 (ru) * | 2005-04-29 | 2009-10-30 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида |
| JP5376948B2 (ja) | 2005-09-13 | 2013-12-25 | ナショナル リサーチ カウンシル オブ カナダ | 腫瘍細胞活性を調節する方法及び組成物 |
| RU2559536C2 (ru) | 2007-03-24 | 2015-08-10 | Джензим Корпорейшн | Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в |
| AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法 |
| EP2222851B1 (en) * | 2007-11-20 | 2017-06-28 | Ionis Pharmaceuticals, Inc. | Modulation of cd40 expression |
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| WO2011063523A1 (en) | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| MY165507A (en) | 2011-02-03 | 2018-03-28 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
| CN105969773A (zh) | 2011-02-03 | 2016-09-28 | 米尔纳医疗股份有限公司 | Mir-124的合成模拟物 |
| AU2012228010B2 (en) | 2011-03-15 | 2016-08-25 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| EP3533873A1 (en) | 2011-09-14 | 2019-09-04 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
| CA2862739A1 (en) | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| JP2015518712A (ja) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | Ｍｅｃｐ２発現を調節するための組成物及び方法 |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| CA2954475C (en) | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
| EP3256592A4 (en) * | 2015-02-13 | 2018-09-12 | Translate Bio Ma, Inc. | Compositions and methods for modulating rna |
| CN107709555A (zh) * | 2015-05-15 | 2018-02-16 | 达尔马科恩有限公司 | 用于Cas9介导的基因编辑的合成的单向导RNA |
| PE20180800A1 (es) | 2015-07-10 | 2018-05-09 | Ionis Pharmaceuticals Inc | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) |
| FR3069156B1 (fr) * | 2017-07-21 | 2019-08-09 | Universite de Bordeaux | Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
| JPH06505704A (ja) | 1990-09-20 | 1994-06-30 | ギリアド サイエンシズ，インコーポレイテッド | 改変ヌクレオシド間結合 |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| AUPM301293A0 (en) | 1993-12-17 | 1994-01-20 | University Of Melbourne, The | Methods and reagents for sperm analysis |
| US5695995A (en) * | 1994-05-06 | 1997-12-09 | Fred Hutchinson Cancer Research Center | Neurogenic differentiation (neurod) genes |
| US5786213A (en) * | 1996-04-18 | 1998-07-28 | Board Of Regents, The University Of Texas System | Inhibition of endogenous gastrin expression for treatment of colorectal cancer |
| US5739310A (en) * | 1996-04-23 | 1998-04-14 | Fred Hutchinson Cancer Research Center | Ribosomes as vectors for RNA |
| US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
| US5959097A (en) * | 1998-11-20 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEK2 expression |
| WO2000034469A1 (en) * | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| US5958773A (en) * | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| US5948680A (en) * | 1998-12-17 | 1999-09-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of Elk-1 expression |
| IL144975A0 (en) | 1999-02-26 | 2002-06-30 | Univ British Columbia | A composition containing an antisense oligonucleotide |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
-
2000
- 2000-09-11 US US09/659,791 patent/US6383808B1/en not_active Expired - Lifetime
-
2001
- 2001-09-10 WO PCT/US2001/028235 patent/WO2002022635A1/en not_active Ceased
- 2001-09-10 AU AU2001290706A patent/AU2001290706A1/en not_active Abandoned
- 2001-09-10 EP EP01970728A patent/EP1325019B1/en not_active Expired - Lifetime
- 2001-09-10 JP JP2002526886A patent/JP4397585B2/ja not_active Expired - Fee Related
- 2001-09-10 DE DE60143901T patent/DE60143901D1/de not_active Expired - Lifetime
- 2001-09-10 US US10/380,124 patent/US20040053874A1/en not_active Abandoned
- 2001-09-10 AT AT01970728T patent/ATE496127T1/de not_active IP Right Cessation
-
2009
- 2009-08-21 JP JP2009191924A patent/JP2010043086A/ja active Pending
-
2013
- 2013-07-29 JP JP2013156811A patent/JP2014027936A/ja active Pending